Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: The Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study

Annals of the Rheumatic Diseases

Volumn 70, Issue 6, 2011, Pages 1091-1094

  McQueen, Fiona ^a,b   Lloyd, Richard ^a   Doyle, Anthony ^a,b   Robinson, Elizabeth ^a   Lobo, Maria ^b   Exeter, Melissa ^b   Taylor, William J ^c,d   Jones, Peter ^a   Reid, Ian R ^a,b   Dalbeth, Nicola ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d Hutt Valley District Health Board   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE DISEASE; BONE EDEMA; BONE EROSION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; EDEMA; FEMALE; HUMAN; HUMAN TISSUE; JAW OSTEONECROSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT DURATION; VISUAL ANALOG SCALE;

ADULT; ARTHRITIS, PSORIATIC; BONE DENSITY CONSERVATION AGENTS; BONE MARROW DISEASES; DIPHOSPHONATES; DISEASE PROGRESSION; EDEMA; EPIDEMIOLOGIC METHODS; FEMALE; FINGER JOINT; HUMANS; IMIDAZOLES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; TREATMENT OUTCOME; WRIST JOINT;

EID: 79955821249     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.142539     Document Type: Article

References (22)

1. Gladman D D. Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint diseases? Ann Rheum Dis 2006 ; 65 (Suppl 3) :iii22-4. (Pubitemid 44629096) (Pubitemid 44629096)
2. Marsal S, Armadans-Gil L, Martínez M, et al. Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology (Oxford) 1999 ; 38 : 332-7. (Pubitemid 29507183) (Pubitemid 29507183)
3. McQueen FM, Ostendorf B. What is MRI bone oedema in rheumatoid arthritis and why does it matter? Arthritis Res Ther 2006 ; 8 : 222.
4. Dalbeth N, Smith T, Gray S, et al. Cellular characterisation of magnetic resonance imaging bone oedema in rheumatoid arthritis; implications for pathogenesis of erosive disease. Ann Rheum Dis 2009 ; 68 : 279-82.
5. McQueen F, Lassere M, Østergaard M. Magnetic resonance imaging in psoriatic arthritis: a review of the literature. Arthritis Res Ther 2006 ; 8 : 207.
6. Sato K, Takayanagi H. Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr Opin Rheumatol 2006 ; 18 : 419-26. (Pubitemid 44297289) (Pubitemid 44297289)
7. Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKLmediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003 ; 111 : 821-31. (Pubitemid 37074957) (Pubitemid 37074957)
8. Jarrett SJ, Conaghan PG, Sloan VS, et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 2006 ; 54 : 1410-14.
9. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006 ; 54 : 2665-73. (Pubitemid 44205029) (Pubitemid 44205029)
10. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006 ; 144 : 753-61. (Pubitemid 46780635) (Pubitemid 46780635)
11. Tan YM, Østergaard M, Doyle A, et al. MRI bone oedema scores are higher in the arthritis mutilans form of psoriatic arthritis and correlate with high radiographic scores for joint damage. Arthritis Res Ther 2009 ; 11 : R2.
12. McQueen F, Lassere M, Bird P, et al. Developing a magnetic resonance imaging scoring system for peripheral psoriatic arthritis. J Rheumatol 2007 ; 34 : 859-61. (Pubitemid 46641399) (Pubitemid 46641399)
13. Green JR. Preclinical pharmacology of zoledronic acid. Semin Oncol 2002 ; 29 ( 6 Suppl 21 ): 3-11. (Pubitemid 36222937) (Pubitemid 36222937)
14. Dalbeth N, Pool B, Smith T, et al. Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Res Ther 2010 ; 12 : R164.
15. Redlich K, Hayer S, Maier A, et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002 ; 46 : 785-92. (Pubitemid 34214261) (Pubitemid 34214261)
16. Sims NA, Green JR, Glatt M, et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum 2004 ; 50 : 2338-46. (Pubitemid 38924414) (Pubitemid 38924414)
17. Maksymowych WP, Lambert R, Jhangri GS, et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 2001 ; 28 : 144-55. (Pubitemid 32062038) (Pubitemid 32062038)
18. McQueen FM, Benton N, Perry D, et al. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 2003 ; 48 : 1814-27. (Pubitemid 36828675) (Pubitemid 36828675)
19. Marzo-Ortega H, McGonagle D, Rhodes LA, et al. Efficacy of infliximab on MRIdetermined bone oedema in psoriatic arthritis. Ann Rheum Dis 2007 ; 66 : 778-81. (Pubitemid 46846697) (Pubitemid 46846697)
20. Anandarajah AP, Schwarz EM, Totterman S, et al. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis 2008 ; 67 : 296-301. (Pubitemid 351281261) (Pubitemid 351281261)
21. Bugatti S, Caporali R, Manzo A, et al. Involvement of subchondral bone marrow in rheumatoid arthritis: lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment. Arthritis Rheum 2005 ; 52 : 3448-59. (Pubitemid 41612211) (Pubitemid 41612211)
22. Davis JC Jr, Huang F, Maksymowych W. New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate. Rheum Dis Clin North Am 2003 ; 29 : 481-94. (Pubitemid 36993537) (Pubitemid 36993537)